JP6971574B2 - 合成メッセンジャーｒｎａによるヒト人工多能性幹細胞のフィーダーフリー誘導 - Google Patents

合成メッセンジャーｒｎａによるヒト人工多能性幹細胞のフィーダーフリー誘導 Download PDF

Info

Publication number
JP6971574B2
JP6971574B2 JP2016514171A JP2016514171A JP6971574B2 JP 6971574 B2 JP6971574 B2 JP 6971574B2 JP 2016514171 A JP2016514171 A JP 2016514171A JP 2016514171 A JP2016514171 A JP 2016514171A JP 6971574 B2 JP6971574 B2 JP 6971574B2
Authority
JP
Japan
Prior art keywords
cells
cell
reprogramming
mrna
synthetic mrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016514171A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016521541A (ja
JP2016521541A5 (enExample
Inventor
ジウ ワン，
Original Assignee
アリール バイオテクノロジー アンド ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリール バイオテクノロジー アンド ファーマシューティカルズ， インコーポレイテッド filed Critical アリール バイオテクノロジー アンド ファーマシューティカルズ， インコーポレイテッド
Publication of JP2016521541A publication Critical patent/JP2016521541A/ja
Publication of JP2016521541A5 publication Critical patent/JP2016521541A5/ja
Priority to JP2021121453A priority Critical patent/JP2021166553A/ja
Application granted granted Critical
Publication of JP6971574B2 publication Critical patent/JP6971574B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/605—Nanog
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/608—Lin28
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Transplantation (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016514171A 2013-05-13 2014-05-30 合成メッセンジャーｒｎａによるヒト人工多能性幹細胞のフィーダーフリー誘導 Active JP6971574B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021121453A JP2021166553A (ja) 2013-05-13 2021-07-26 合成メッセンジャーｒｎａによるヒト人工多能性幹細胞のフィーダーフリー誘導

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/893,166 US10155929B2 (en) 2012-05-13 2013-05-13 Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA
PCT/US2014/040362 WO2014190361A2 (en) 2013-05-13 2014-05-30 Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2019134561A Division JP2019170405A (ja) 2019-07-22 2019-07-22 合成メッセンジャーｒｎａによるヒト人工多能性幹細胞のフィーダーフリー誘導
JP2021121453A Division JP2021166553A (ja) 2013-05-13 2021-07-26 合成メッセンジャーｒｎａによるヒト人工多能性幹細胞のフィーダーフリー誘導

Publications (3)

Publication Number Publication Date
JP2016521541A JP2016521541A (ja) 2016-07-25
JP2016521541A5 JP2016521541A5 (enExample) 2017-05-25
JP6971574B2 true JP6971574B2 (ja) 2021-11-24

Family

ID=51939013

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016514171A Active JP6971574B2 (ja) 2013-05-13 2014-05-30 合成メッセンジャーｒｎａによるヒト人工多能性幹細胞のフィーダーフリー誘導
JP2021121453A Withdrawn JP2021166553A (ja) 2013-05-13 2021-07-26 合成メッセンジャーｒｎａによるヒト人工多能性幹細胞のフィーダーフリー誘導

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021121453A Withdrawn JP2021166553A (ja) 2013-05-13 2021-07-26 合成メッセンジャーｒｎａによるヒト人工多能性幹細胞のフィーダーフリー誘導

Country Status (8)

Country Link
US (1) US10155929B2 (enExample)
EP (2) EP3904504A1 (enExample)
JP (2) JP6971574B2 (enExample)
CN (1) CN105555949A (enExample)
HK (2) HK1224335A1 (enExample)
MX (2) MX2015015840A (enExample)
SG (2) SG10202006695TA (enExample)
WO (1) WO2014190361A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
DK3260140T3 (da) 2011-12-05 2021-04-19 Factor Bioscience Inc Fremgangsmåder og produkter til transficering af celler
EP3561054B1 (en) * 2012-05-13 2023-07-05 Allele Biotechnology And Pharmaceuticals, Inc. Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna
US10155929B2 (en) * 2012-05-13 2018-12-18 Allele Biotechnology & Pharmaceuticals, Inc. Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA
US10119150B2 (en) 2012-05-13 2018-11-06 Allele Biotechnology & Pharmaceuticals, Inc. Feeder-free Derivation of human-induced pluripotent stem cells with synthetic messenger RNA
CA2876868A1 (en) * 2012-06-13 2013-12-19 Stemgent, Inc. Methods of preparing pluripotent stem cells
BR122019025681B1 (pt) 2012-11-01 2023-04-18 Factor Bioscience Inc Método para inserir uma sequência de ácido nucleico em uma localização segura de um genoma de uma célula
WO2015117021A1 (en) 2014-01-31 2015-08-06 Factor Bioscience Inc. Methods and products for nucleic acid production and delivery
CA2950582C (en) * 2014-05-30 2020-09-22 Allele Biotechnology And Pharmaceuticals, Inc. Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna
EP3543339A1 (en) 2015-02-13 2019-09-25 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
WO2019241569A1 (en) * 2018-06-16 2019-12-19 Luigi Warren Reprogramming cells with synthetic messenger rna
CN105567642B (zh) * 2016-02-01 2019-07-12 中国科学院生物物理研究所 一种着色性干皮病人多能干细胞的制备方法
CN109803977B (zh) 2016-08-17 2023-03-17 菲克特生物科学股份有限公司 核酸产品及其施用方法
CA3043372A1 (en) 2016-11-16 2018-05-24 Allele Biotechnology & Pharmaceuticals, Inc. Induction of pancreatic beta cells by stem cell differentiation with rna
EP3564362A4 (en) * 2016-12-28 2020-07-08 Kyoto Prefectural Public University Corporation SKELETAL MUSCLE CELLS AND THEIR INDUCTION METHOD
CN107142244B (zh) * 2017-07-03 2019-12-20 广州润虹医药科技股份有限公司 培养基及其用途与诱导多能干细胞向间充质干细胞转化的方法
EP3652200A4 (en) 2017-07-13 2021-04-28 Allele Biotechnology And Pharmaceuticals, Inc. INDUCTION OF NEURAL PROGENITOR CELLS, OLIGODENDROCYTE AND OLIGODENDROCYTE PROGENITOR CELLS BY DIFFERENTIATION OF STEM CELLS USING MARKET TRANSCRIPTION FACTORS
SG11202008839WA (en) * 2018-03-13 2020-10-29 Univ Leland Stanford Junior Transient cellular reprogramming for reversal of cell aging
EP3969571A4 (en) 2019-05-14 2023-05-24 Aleph Farms Ltd. AGGREGATES OF PLURIPOTENT CELLS AND THEIR USE
WO2021003462A1 (en) 2019-07-03 2021-01-07 Factor Bioscience Inc. Cationic lipids and uses thereof
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
JP2022104813A (ja) 2020-12-29 2022-07-11 アイ ピース，インコーポレイテッド リプログラミング因子を導入された細胞の培養方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260432A (en) 1989-06-22 1993-11-09 Sloan-Kettering Institute For Cancer Research Human gamma retinoic acid receptor DNA
JP2008307007A (ja) * 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
SG160248A1 (en) * 2008-09-18 2010-04-29 Agency Science Tech & Res Use of novel monoclonal antibodies targeting human embryonic stem cells to characterize and kill induced pluripotent stem cells
EP2881461A1 (en) 2008-11-21 2015-06-10 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Reprogramming cells toward a pluripotent state
WO2010108126A2 (en) 2009-03-19 2010-09-23 Fate Therapeutics, Inc. Reprogramming compositions and methods of using the same
WO2011016588A1 (en) * 2009-08-07 2011-02-10 Kyoto University Method of efficiently establishing induced pluripotent stem cells
CN102190731B (zh) * 2010-03-09 2016-01-27 中国科学院上海生命科学研究院 用人工转录因子诱导产生多能干细胞
WO2011140397A2 (en) * 2010-05-05 2011-11-10 The Regents Of The University Of California Office Of The President Stem cell defined media for xeno-free and feeder free conditions and uses thereof
WO2011142832A2 (en) 2010-05-13 2011-11-17 Whitehead Institute For Biomedical Research Stem cells derived under low oxygen conditions
WO2012012708A1 (en) 2010-07-22 2012-01-26 Regents Of The University Of Minnesota Induced pluripotent stem cells
WO2012144906A1 (en) * 2011-04-22 2012-10-26 Prosensa Technologies B.V. New compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type 1 (dm1)
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
CA2864702A1 (en) 2012-02-22 2013-08-29 Amgen Inc. Autologous mammalian models derived from induced pluripotent stem cells and related methods
EP3561054B1 (en) 2012-05-13 2023-07-05 Allele Biotechnology And Pharmaceuticals, Inc. Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna
US10155929B2 (en) 2012-05-13 2018-12-18 Allele Biotechnology & Pharmaceuticals, Inc. Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA

Also Published As

Publication number Publication date
JP2016521541A (ja) 2016-07-25
WO2014190361A2 (en) 2014-11-27
MX2021005715A (es) 2021-07-21
HK1224335A1 (zh) 2017-08-18
WO2014190361A3 (en) 2015-07-30
SG10202006695TA (en) 2020-08-28
EP2997130A2 (en) 2016-03-23
EP3904504A1 (en) 2021-11-03
US20130302295A1 (en) 2013-11-14
HK1222675A1 (zh) 2017-07-07
CN105555949A (zh) 2016-05-04
US10155929B2 (en) 2018-12-18
EP2997130A4 (en) 2017-03-01
JP2021166553A (ja) 2021-10-21
SG11201509368PA (en) 2015-12-30
MX2015015840A (es) 2016-08-11

Similar Documents

Publication Publication Date Title
JP6971574B2 (ja) 合成メッセンジャーｒｎａによるヒト人工多能性幹細胞のフィーダーフリー誘導
JP6448531B2 (ja) 合成メッセンジャーｒｎａを使用したヒト人工多能性幹細胞のフィーダーフリー誘導
US10435711B2 (en) Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA
KR102361849B1 (ko) 합성 메신저 rna를 사용한 인간-유도된 만능 줄기 세포의 무-피더 유래
JP2019170405A (ja) 合成メッセンジャーｒｎａによるヒト人工多能性幹細胞のフィーダーフリー誘導
HK40015744A (en) Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna
HK40015744B (en) Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna
HK1204005B (zh) 使用合成的信使rna无饲养细胞地衍生人类诱导性多能干细胞
HK40013817A (en) Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna
HK40013817B (en) Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170405

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170405

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180530

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181029

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190722

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20190722

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20190730

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190829

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20190830

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20191101

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20191106

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200408

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20210122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210420

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210521

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210726

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210820

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20211006

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20211006

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211102

R150 Certificate of patent or registration of utility model

Ref document number: 6971574

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250